BG108515A - Pharmaceutical formulation comprising a proton pump inhibitor and antiacids - Google Patents

Pharmaceutical formulation comprising a proton pump inhibitor and antiacids

Info

Publication number
BG108515A
BG108515A BG108515A BG10851504A BG108515A BG 108515 A BG108515 A BG 108515A BG 108515 A BG108515 A BG 108515A BG 10851504 A BG10851504 A BG 10851504A BG 108515 A BG108515 A BG 108515A
Authority
BG
Bulgaria
Prior art keywords
agent
proton pump
antiacids
pharmaceutical formulation
pump inhibitor
Prior art date
Application number
BG108515A
Other languages
Bulgarian (bg)
English (en)
Inventor
Bruno Criere
Nourredine Nouri
Ake Pilbrant
Pascal Suplie
Jean-Marc Zuccarelli
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BG108515A publication Critical patent/BG108515A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BG108515A 2001-07-16 2004-01-06 Pharmaceutical formulation comprising a proton pump inhibitor and antiacids BG108515A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01401896 2001-07-16

Publications (1)

Publication Number Publication Date
BG108515A true BG108515A (en) 2005-02-28

Family

ID=8182807

Family Applications (1)

Application Number Title Priority Date Filing Date
BG108515A BG108515A (en) 2001-07-16 2004-01-06 Pharmaceutical formulation comprising a proton pump inhibitor and antiacids

Country Status (24)

Country Link
US (2) US20040219211A1 (xx)
EP (1) EP1416922A1 (xx)
JP (1) JP2004536855A (xx)
KR (1) KR20040018463A (xx)
CN (1) CN100469366C (xx)
AR (1) AR034757A1 (xx)
AU (1) AU2002316020B2 (xx)
BG (1) BG108515A (xx)
BR (1) BR0211117A (xx)
CA (1) CA2453290A1 (xx)
CO (1) CO5550417A2 (xx)
HU (1) HUP0401941A3 (xx)
IL (1) IL159584A0 (xx)
IS (1) IS7111A (xx)
MX (1) MXPA04000385A (xx)
MY (1) MY136137A (xx)
NO (1) NO20040178L (xx)
NZ (1) NZ530511A (xx)
PL (1) PL367686A1 (xx)
RU (1) RU2301662C2 (xx)
UA (1) UA75673C2 (xx)
UY (1) UY27385A1 (xx)
WO (1) WO2003007917A1 (xx)
ZA (1) ZA200400285B (xx)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1596100A (zh) 2001-09-28 2005-03-16 麦克内尔-Ppc股份有限公司 可食用组合物及含可食用外壳的制剂
DE10304403A1 (de) 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
JP3841804B2 (ja) * 2003-10-15 2006-11-08 富士化学工業株式会社 口腔内速崩壊性錠剤用の組成物
US8349361B2 (en) 2003-10-15 2013-01-08 Fuji Chemical Industry Co., Ltd. Composition for rapid disintegrating tablet in oral cavity
CN100438914C (zh) * 2003-10-15 2008-12-03 富士化学工业株式会社 用于口腔内快速崩解的片剂的组合物
EP1682087A1 (en) * 2003-11-07 2006-07-26 Takeda Pharmaceutical Company Limited Chewable tablet
US20050281876A1 (en) 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
EP1621187A1 (en) * 2004-07-26 2006-02-01 AstraZeneca AB Pharmaceutical multiparticulate tablet formulations and process for their preparation
US8758814B2 (en) 2004-10-08 2014-06-24 Mcneil-Ppc, Inc. Chewable enteric coated aspirin tablets
US8057820B2 (en) 2004-10-08 2011-11-15 Mcneil-Ppc, Inc. Enteric coated aspirin granules comingled with binder
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
DE102005024614A1 (de) * 2005-05-25 2006-11-30 Röhm Gmbh Verwendung von Polymermischungen zur Herstellung von überzogenen Arzneiformen sowie Arzneiform mit polymerem Mischüberzug
US20080166407A1 (en) * 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
CN100431526C (zh) * 2005-11-07 2008-11-12 上海艾力斯医药科技有限公司 一种酸敏感型药物的快速崩解片剂
CN101120930B (zh) * 2006-08-11 2010-09-29 石药集团中奇制药技术（石家庄）有限公司 一种奥美拉唑组合物及其制备方法
MX2010007578A (es) * 2008-01-10 2010-08-03 Evonik Roehm Gmbh Preparacion nutriceutica o farmaceutica revestida con una liberacion acelerada controlada de sustancia activa.
MX2010007579A (es) * 2008-01-10 2010-08-03 Evonik Roehm Gmbh Preparacion nutriceutica o farmaceutica revestida con una liberacion de sustancia activa de impulsion mejorada.
EP2262534B1 (en) * 2008-03-10 2014-07-16 Bayer Consumer Care AG Palatable solid composition comprising antacid and saliva stimulant
EA021792B1 (ru) * 2008-03-11 2015-09-30 Такеда Фармасьютикал Компани Лимитед Твердый препарат, растворяющийся во рту
US9101565B2 (en) * 2008-11-17 2015-08-11 Takeda Nycomed As Dissolution stability of calcium carbonate tablets
MX2013006247A (es) * 2010-12-03 2014-01-31 Takeda Pharmaceutical Tableta oralmente desintegradora.
CN102085188B (zh) * 2011-01-14 2013-01-02 寿光富康制药有限公司 一种兰索拉唑肠溶微丸的制备方法
CN102078616A (zh) * 2011-01-28 2011-06-01 北京虹湾医药技术有限公司 埃索美拉唑碳酸氢钠组合物
US8277842B1 (en) * 2012-01-20 2012-10-02 Dart Neuroscience (Cayman) Ltd. Enteric-coated HT-2157 compositions and methods of their use
CN102631327B (zh) * 2012-05-14 2013-08-28 海南葫芦娃制药有限公司 一种奥美拉唑肠溶微丸及其制备方法
CN103479593B (zh) * 2013-05-10 2014-10-08 青岛双鲸药业有限公司 一种奥美拉唑肠溶片的制备方法
JP6156037B2 (ja) * 2013-10-03 2017-07-05 ライオン株式会社 固形医薬製剤組成物
CN103784414B (zh) * 2013-12-18 2018-01-30 北京华禧联合科技发展有限公司 一种埃索美拉唑肠溶片及其制备方法
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
AU2017215530B2 (en) * 2016-02-03 2019-09-12 Novartis Ag Galenic formulations of organic compounds
WO2017185123A1 (en) * 2016-04-29 2017-11-02 Alan Thompson Veterinary composition
US10076494B2 (en) * 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN108434117A (zh) * 2018-03-29 2018-08-24 成都通德药业有限公司 一种奥美拉唑肠溶胶囊的制备方法
RU2727506C1 (ru) * 2019-09-09 2020-07-22 Пивипи Лабс Пте. Лтд. Средство для лечения эректильной дисфункции
KR102531045B1 (ko) * 2020-01-23 2023-05-11 한미약품 주식회사 프로톤 펌프 저해제 및 제산제를 포함하는 약제학적 복합제제
WO2022103233A1 (ko) * 2020-11-13 2022-05-19 (주)휴온스 라베프라졸 및 제산제를 포함하는 약제학적 복합제제 및 이의 제조방법
CN114617852B (zh) * 2020-12-10 2023-06-27 昆药集团股份有限公司 一种奥美拉唑肠溶制剂及其制备方法
CN117500923A (zh) 2021-04-07 2024-02-02 巴特尔纪念研究院 用于鉴定和使用非病毒载体的快速设计、构建、测试和学习技术

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2516408B2 (ja) * 1988-08-18 1996-07-24 エスエス製薬株式会社 被覆顆粒を含む錠剤
DE4122217C2 (de) * 1991-07-04 1997-02-13 Merz & Co Gmbh & Co Verfahren zur Herstellung mechanisch stabiler, gut zerfallender Komprimate aus kleinen wirkstoffhaltigen Formkörpern
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
PT1078628E (pt) * 1994-07-08 2009-01-27 Astrazeneca Ab Forma de dosagem em comprimidos com unidades múltiplas
SE9600071D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
DE19617487A1 (de) * 1996-05-02 1997-11-06 Merck Patent Gmbh Geschmacksverbesserung von Arzneimittelwirkstoffen
JP3961596B2 (ja) * 1996-10-15 2007-08-22 富士化学工業株式会社 無機制酸剤含有速分散性造粒物、その製造方法及び用時懸濁内服制酸剤
US6024981A (en) * 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
SK180499A3 (en) * 1997-07-01 2001-08-06 Pfizer Sertraline salts and sustained-release dosage forms of sertraline
FR2766089B1 (fr) * 1997-07-21 2000-06-02 Prographarm Lab Comprime multiparticulaire perfectionne a delitement rapide
CN1195500C (zh) * 1998-05-18 2005-04-06 武田药品工业株式会社 可口腔崩解的片剂
AU5248900A (en) * 1999-06-18 2001-01-09 Takeda Chemical Industries Ltd. Quickly disintegrating solid preparations
DE19954653B4 (de) * 1999-11-13 2006-01-19 Contitech Profile Gmbh Extruder zur Aufbereitung von Kautschukmischungen
US6656492B2 (en) * 2000-06-30 2003-12-02 Yamanouchi Pharmaceutical Co., Ltd. Quick disintegrating tablet in buccal cavity and manufacturing method thereof
US6749867B2 (en) * 2000-11-29 2004-06-15 Joseph R. Robinson Delivery system for omeprazole and its salts
EP1341528B1 (en) * 2000-12-07 2012-01-18 Nycomed GmbH Rapidly disintegrating tablet comprising an acid-labile active ingredient

Also Published As

Publication number Publication date
NZ530511A (en) 2005-06-24
CN1555256A (zh) 2004-12-15
KR20040018463A (ko) 2004-03-03
RU2004101061A (ru) 2005-04-20
JP2004536855A (ja) 2004-12-09
IS7111A (is) 2004-01-15
AU2002316020B2 (en) 2007-03-15
ZA200400285B (en) 2005-06-29
MY136137A (en) 2008-08-29
UY27385A1 (es) 2003-02-28
BR0211117A (pt) 2004-06-22
CA2453290A1 (en) 2003-01-30
WO2003007917A1 (en) 2003-01-30
IL159584A0 (en) 2004-06-01
NO20040178L (no) 2004-03-16
US20110135722A1 (en) 2011-06-09
CO5550417A2 (es) 2005-08-31
EP1416922A1 (en) 2004-05-12
CN100469366C (zh) 2009-03-18
HUP0401941A2 (hu) 2005-01-28
RU2301662C2 (ru) 2007-06-27
PL367686A1 (en) 2005-03-07
MXPA04000385A (es) 2004-05-04
HUP0401941A3 (en) 2008-04-28
US20040219211A1 (en) 2004-11-04
UA75673C2 (en) 2006-05-15
AR034757A1 (es) 2004-03-17

Similar Documents

Publication Publication Date Title
BG108515A (en) Pharmaceutical formulation comprising a proton pump inhibitor and antiacids
MX9706785A (es) Formas de dosificacion farmaceutica oral que comprenden un inhibidor de la bomba de protones y un agente antiacido o alginato.
MXPA03012041A (es) Sistema de administracion controlada de farmacos de retencion gastrica.
MY119212A (en) Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a nsaid
AP1665A (en) Tamper-resistant oral opioid agonist formulations.
MX9706769A (es) Formas de dosificacion farmaceutica que comprenden un inhibidor de la bomba de protones y un agente procinetico.
MX9604497A (es) Nueva formulacion farmaceutica y procedimiento.
EP1734041A3 (en) Platelet ADP receptor inhibitors
EE05670B1 (et) Ramipriil kardiovaskulaarsete haigusjuhtude „rahoidmiseks
RS20120514A2 (xx) Jednodnevne formulacije oksikodona
CA2460140A1 (en) Compositions for treatment of common cold
BR9913239A (pt) Comprimido bioadesivo bucal de liberação prolongada
CA2348086A1 (en) Controlled-release pharmaceutical formulations
CA2457361A1 (en) Opioid agonist formulations with releasable and sequestered antagonist
WO2005011586A3 (en) Treatment and preventi0n of cardiovascular events
WO2002099388A3 (en) Benzodiazepine bradykinin antagonists
UY27296A1 (es) Composición farmacéutica que contiene mosaprida y pancreatina
WO2003082196A3 (en) Combination therapy using trefoil peptides
WO2003094921A3 (de) Verwendung von hemmern der egfr-vermittelten signaltransduktion zur behandlung von gutartiger prostatahyperplasie (bph)/prostatahypertrophie
NO20054216L (no) Anvendelse av dipyridamol i kombinasjon med acetylsalisylsyre og en angiotensin II antagonist for forhindring av slag
WO2007016128A3 (en) Magnesium salt proton pump inhibitor dosage forms
EP0870502A3 (en) Use of adenosine uptake inhibitors for the manufacture of a medicament for the treatment of pancreatitis
EP0818439A3 (en) Imide derivatives
IL158762A0 (en) Prevention of addiction in pain management
MXPA03005384A (es) Composiciones framaceuticas de un inhibidor de bomba de proton revestido no enterico con una combinacion de sal de bicarbonato y sal de carbonato.